Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

ValiRx plc

Healthcare GB VAL

0.1805GBX
-0.01(5.25%)

Last update at 2026-06-12T07:09:00Z

Day Range

0.180.18
LowHigh

52 Week Range

0.220.88
LowHigh

Fundamentals

  • Previous Close 0.19
  • Market Cap2.15M
  • Volume1800000
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-1.76313M
  • Revenue TTM0.05M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.05M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -2.13045M -2.30296M -2.59883M -1.68060M -1.54350M
Minority interest 0.09M 0.09M 0.04M 0.03M -0.15589M
Net income -1.91569M -2.03770M -2.40616M -1.54719M -1.46832M
Selling general administrative 1.98M 1.89M 1.50M 1.22M 1.43M
Selling and marketing expenses - 0.22M - - -
Gross profit -0.21722M -0.24604M - - -
Reconciled depreciation 0.27M 0.25M 0.21M 0.23M 0.23M
Ebit -2.12918M -2.29854M -2.59338M -1.67784M -1.65063M
Ebitda -1.86218M -2.04434M -2.38145M -1.44905M -1.29913M
Depreciation and amortization 0.27M 0.25M 0.21M 0.23M 0.35M
Non operating income net other - - - - -
Operating income -2.14167M -2.29854M -2.59338M -1.67784M -1.65063M
Other operating expenses 2.19M 2.31M 2.59M 1.68M 1.65M
Interest expense 0.00128M 0.00442M 0.00546M 0.00277M 0.01M
Tax provision -0.12770M -0.17517M -0.19267M -0.13341M -0.07518M
Interest income 0.01M 0.00000M - - -
Net interest income 0.01M -0.00442M -0.00546M -0.00277M -0.01488M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.12770M -0.17517M -0.19267M -0.13341M -0.07518M
Total revenue 0.05M 0.00960M 0.00000M 0.00000M 0.00000M
Total operating expenses 2.19M 2.05M 2.59M 1.68M 1.65M
Cost of revenue 0.00000M 0.26M - - -
Total other income expense net 0.01M -0.00442M -0.00546M -0.00277M 0.11M
Discontinued operations - - - - -
Net income from continuing ops -2.00276M -2.12778M -2.40616M -1.54719M -1.46832M
Net income applicable to common shares - - -2.36649M -1.51821M -1.44325M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 4.26M 3.13M 3.98M 3.52M 4.94M
Intangible assets 0.53M 0.72M 0.90M 1.11M 1.33M
Earning assets - - - - -
Other current assets 0.17M 0.32M - 0.21M 0.14M
Total liab 0.35M 0.23M 0.15M 0.11M 0.18M
Total stockholder equity 4.32M 3.22M 4.05M 3.60M 4.91M
Deferred long term liab - - - - -
Other current liab 0.07M 0.06M - 0.04M 0.04M
Common stock 0.37M 0.10M 9.70M 9.67M 9.67M
Capital stock 0.37M 0.10M 9.70M 0.07M 9.67M
Retained earnings -38.49179M -36.68134M -34.64364M -32.29251M -30.91973M
Other liab - - - - -
Good will 1.60M 1.60M 1.60M 1.60M 1.60M
Other assets - - - - -
Cash 1.56M 0.17M 1.14M 0.59M 1.85M
Cash and equivalents - - - - -
Total current liabilities 0.35M 0.21M 0.13M 0.07M 0.12M
Current deferred revenue - -0.12464M - - -
Net debt -1.54412M -0.15261M -1.09977M -0.53495M -1.77584M
Short term debt 0.01M 0.01M 0.02M 0.02M 0.01M
Short long term debt 0.01M 0.01M 0.00996M 0.00963M 0.00551M
Short long term debt total 0.01M 0.02M 0.04M 0.06M 0.07M
Other stockholder equity 42.43M 39.80M 29.00M 26.22M 26.16M
Property plant equipment - - 0.00556M 0.01M 0.02M
Total current assets 1.90M 0.57M 1.46M 0.80M 1.98M
Long term investments - - - - -
Net tangible assets - - 1.54M 0.89M 1.98M
Short term investments - - - - -
Net receivables 0.10M 0.10M 0.13M 0.21M 0.10M
Long term debt 0.00139M 0.01M 0.02M 0.04M 0.04M
Inventory 0.07M 0.07M - - -
Accounts payable 0.15M 0.12M 0.11M 0.05M 0.11M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 1.68M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - 9.67M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.72M - - -
Deferred long term asset charges - - - - -
Non current assets total 2.37M 2.56M 2.51M 2.72M 2.95M
Capital lease obligations - 0.00000M 0.00568M 0.01M 0.02M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -0.03816M -0.30618M - 0.00000M -0.09129M
Change to liabilities - - 0.06M -0.06051M -0.95727M
Total cashflows from investing activities -0.03816M -0.30618M - - -0.09129M
Net borrowings -0.01021M -0.00996M -0.02225M -0.01432M -0.03250M
Total cash from financing activities 3.00M 1.12M 2.26M 0.00734M 3.85M
Change to operating activities - - - - -
Net income -2.14167M -2.29854M -2.59338M -1.67784M -1.65063M
Change in cash 1.38M -0.96279M 0.54M -1.25323M 1.85M
Begin period cash flow 0.17M 1.14M 0.59M 1.85M -0.00563M
End period cash flow 1.56M 0.17M 1.14M 0.59M 1.85M
Total cash from operating activities -1.58486M -1.77235M -1.71225M -1.26057M -1.91072M
Issuance of capital stock 3.37M 1.30M 2.49M 0.02M 4.13M
Depreciation 0.27M 0.25M 0.21M 0.23M 0.23M
Other cashflows from investing activities - -0.01500M - - -
Dividends paid - - - - -
Change to inventory 0.00000M -0.06900M - - -
Change to account receivables 0.01M -0.01380M -0.06089M -0.00619M 0.02M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.36022M -0.17430M -0.21808M -0.00900M -0.19817M
Change to netincome - - 0.44M 0.10M 0.24M
Capital expenditures 0.04M 0.31M 0.00000M 0.00000M 0.09M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.14M 0.05M 0.00021M -0.06670M -0.93393M
Stock based compensation 0.00000M 0.04M 0.54M 0.18M 0.00000M
Other non cash items 0.15M 0.19M 0.13M 0.07M 0.44M
Free cash flow -1.62302M -2.07853M -1.71225M -1.26057M -2.00400M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
VAL
ValiRx plc		 -0.01 5.25% 0.18 - - 43.28 0.66 35.23 -5.9991
GNS
Genus PLC		 28.00 1.29% 2198.00 36.08 26.18 2.53 3.46 2.92 15.38
ONT
Oxford Nanopore Technologies Ltd		 2.00 1.67% 122.00 - - 4.71 2.50 4.23 -8.8899
OXB
Oxford BioMedica PLC		 7.00 1.15% 617.00 - 208.33 4.05 7.60 4.42 308.96
AVCT
Avacta Group PLC		 - -% 68.50 - - 2849.46 1929.84 2525.51 -12.0368

Reports Covered

Stock Research & News

View All

Profile

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19; and CLX001, a peptide nanoparticle formulation that is in pre-clinical trial for destruction of cancer cells. The company also develops and commercializes oncology assets in the veterinary market. It has an agreement with University of Dundee. ValiRx plc was incorporated in 2000 and is based in London, the United Kingdom.

ValiRx plc

20 Wenlock Road, London, United Kingdom, N1 7GU

Key Executives

Name Title Year Born
Dr. Suzanne J. Dilly B.Sc., BSc, Ph.D. CEO & Director 1978
Mr. James Gerry Desler FCA CFO & Exec. Director 1956
Mr. Kumar Nawani Head of Operations NA
Dr. Catherine Jane Tralau-Stewart Ph.D. Chief Scientific Officer NA
Mr. Tarquin Edwards Head of Investor Relations & Communications NA
Mr. Mark Treharne Corp. Devel. Mang. NA
Dr. Mark Eccleston M.B.A., Ph.D. CEO, Director, Member of Scientific & Commercial Advisory Board 1971
Mr. James Gerry Desler FCA CFO, Company Secretary & Executive Director 1945
Mr. Mark Treharne Corporate Development Manager NA
Dr. Andrew Carnegie Head of Strategic Commercial Development NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.